The calcitonin receptor is the main mediator of LAAMA's body weight lowering effects in male mice by Gamakharia, Salome et al.








The calcitonin receptor is the main mediator of LAAMA’s body weight
lowering effects in male mice
Gamakharia, Salome ; Le Foll, Christelle ; Rist, Wolfgang ; Baader-Pagler, Tamara ; Baljuls, Angela ;
Lutz, Thomas A
Abstract: The anorectic action of the pancreatic hormone amylin is mainly mediated through the area
postrema (AP). Amylin activates AP neurons using a heterodimeric receptor (AMY) composed of the
calcitonin receptor (CTR) and the receptor activity modifying protein (RAMP 1, 2 or 3). The aim of the
following experiments is to test the effects of the long acting amylin analogue (LAAMA) in RAMP1/3
knock-out (KO) male mice and in neuronal CTR KO Nestin-CreCTR male mice. In vitro, LAAMA
exerted an equipotent effect on CTR and AMYs that was maintained across species. Following one
week of 45% high fat diet, WT, RAMP1/3 KO and Nestin-CreCTR mice were injected daily for one
week with vehicle or LAAMA. LAAMA decreased body weight gain in WT and in RAMP1/3 KO mice
suggesting that RAMP1/3 are not necessary for LAAMA-induced effects. However, LAAMA was not
able to produce any body lowering and anorectic effects in Nestin-CreCTR mice. This was accompanied
by the absence of any c-Fos signal in the AP opposite to WT control mice. Together, these results
suggest that LAAMA’s effects are mainly mediated through CTR rather than specific AMY. The study
of LAAMA or any amylin receptor agonist in different receptor KO mouse models helps disentangle the
underlying mechanisms used by these molecules.
DOI: https://doi.org/10.1016/j.ejphar.2021.174352






The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Gamakharia, Salome; Le Foll, Christelle; Rist, Wolfgang; Baader-Pagler, Tamara; Baljuls, Angela; Lutz,
Thomas A (2021). The calcitonin receptor is the main mediator of LAAMA’s body weight lowering effects
in male mice. European Journal of Pharmacology, 908:174352.
DOI: https://doi.org/10.1016/j.ejphar.2021.174352
European Journal of Pharmacology 908 (2021) 174352
Available online 15 July 2021
0014-2999/© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
The calcitonin receptor is the main mediator of LAAMA’s body weight 
lowering effects in male mice 
Salome Gamakharia a, Christelle Le Foll a,*, Wolfgang Rist b, Tamara Baader-Pagler b, 
Angela Baljuls b, Thomas A. Lutz a 
a Institute of Veterinary Physiology, University of Zurich, CH-8057, Zurich, Switzerland 
b Boehringer-Ingelheim Pharma, 88400, Biberach, Germany   







A B S T R A C T   
The anorectic action of the pancreatic hormone amylin is mainly mediated through the area postrema (AP). 
Amylin activates AP neurons using a heterodimeric receptor (AMY) composed of the calcitonin receptor (CTR) 
and the receptor activity modifying protein (RAMP 1, 2 or 3). The aim of the following experiments is to test the 
effects of the long acting amylin analogue (LAAMA) in RAMP1/3 knock-out (KO) male mice and in neuronal CTR 
KO Nestin-CreCTR male mice. In vitro, LAAMA exerted an equipotent effect on CTR and AMYs that was main-
tained across species. Following one week of 45% high fat diet, WT, RAMP1/3 KO and Nestin-CreCTR mice were 
injected daily for one week with vehicle or LAAMA. LAAMA decreased body weight gain in WT and in RAMP1/3 
KO mice suggesting that RAMP1/3 are not necessary for LAAMA-induced effects. However, LAAMA was not able 
to produce any body lowering and anorectic effects in Nestin-CreCTR mice. This was accompanied by the absence 
of any c-Fos signal in the AP opposite to WT control mice. Together, these results suggest that LAAMA’s effects 
are mainly mediated through CTR rather than specific AMY. The study of LAAMA or any amylin receptor agonist 
in different receptor KO mouse models helps disentangle the underlying mechanisms used by these molecules.   
1. Introduction 
The pancreatic peptide hormone amylin is produced in response to 
food intake and increased blood glucose levels (Hay et al., 2015; Le Foll 
and Lutz, 2020). Amylin primarily acts on the area postrema (AP) and its 
main effects are the induction of meal termination, the reduction of food 
intake, gastric emptying and body weight (Boyle et al., 2018; Lutz, 
2009). Amylin and its receptor agonist, salmon calcitonin, are also 
known to increase energy expenditure in rodents (Coester et al., 2020; 
Wielinga et al., 2007, 2010; Zhang et al., 2011). 
The amylin receptor (AMY) consists of the calcitonin receptor (CTR) 
core and one of the three receptor activity modifying proteins (RAMP1, 
RAMP2, RAMP3), which form AMY 1–3 respectively. Although CTR 
alone can bind amylin, RAMP increases CTR’s affinity towards it 
(Christopoulos et al., 1999; Hay et al., 2015; McLatchie et al., 1998). 
Most CTR expressing cells in the AP express more than one RAMP sub-
types (Liberini et al., 2016), and AMY1 and AMY3 seem to be the main 
mediators of amylin’s effects (Bailey et al., 2012; Coester et al., 2020). 
The role of RAMP2 and AMY2 in the mediation of food intake and 
metabolism is more elusive, since specific antagonists are not available 
and since the RAMP2 whole body knockout is lethal (Kadmiel et al., 
2011). RAMP and CTR have also been shown to be expressed in the 
medio-basal hypothalamus, lateral hypothalamus as well as in ventral 
tegmental area (Christopoulos et al., 1995, 1999; Coester et al., 2020; 
Sexton et al., 1986, 1994) but co-expression of the various AMY com-
ponents in single cells in these areas has not been tested. 
Amylin activates several intracellular pathways, namely it increases 
intracellular cyclic GMP and ERK phosphorylation which is associated 
with amylin’s food intake reducing effects (Potes et al., 2012; Riediger 
et al., 2001, 2004). In vitro studies show that amylin binding increases 
cAMP, intracellular Ca2+ and beta-arrestin expression (Bower and Hay, 
2016; Hay et al., 2005). Amylin also increases the expression of the 
neuronal activation marker c-Fos in its target cells. 
RAMPs also bind to another member of calcitonin family receptors, 
namely the calcitonin receptor-like receptor (CLR). CLR and RAMP1 
form calcitonin gene-related peptide (CGRP) receptor (CGRPR, 
CGRPR1) but AMY1 can also mediate the effects of CGRP (Bailey et al., 
2012) (possibly representing the CGRPR2). Association of CLR with 
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either RAMP2 or RAMP3 results in formation of adrenomedullin re-
ceptor (ADMR) (Poyner et al., 2002; Qi et al., 2008). These structural 
and functional similarities, between calcitonin family members, com-
plicates studying AMY’s physiology and pharmacology (Barwell et al., 
2012). But, regardless of complex pharmacology, amylin’s food intake 
and body weight reducing effects make it an attractive target for an 
anti-obesity and anti-diabetic drug development, with the amylin 
analogue pramlintide being already on the market (Hoogwerf et al., 
2008; Ravussin et al., 2009). 
In this study, we investigated the in vitro pharmacology of the long- 
acting amylin analogue (LAAMA) and its in vivo effects in RAMP1/3 
knockout (KO) and neuronal CTR KO mice with the goal to shed light on 
the role of RAMPs and CTR in mediating the effects of LAAMA. 
2. Materials and methods 
2.1. Pharmacokinetic (PK) analysis of LAAMA in plasma 
For PK analysis three lean RJHAN:WI male rats were dosed i.v. or s.c. 
with a single dose of 10 or 20 nmol/kg, respectively. Blood samples were 
collected at different timepoints post dosing in Microvette® tubes 0.50 
ml K3EDTA (Sarstedt). The Microvette® tubes were ice-chilled prior to 
sampling. After collection, the blood was gently mixed by inverting the 
tube several times and stored upright on ice until centrifugation. Blood 
samples were centrifuged for 5 min at 8.300×g at 4 ◦C. After centrifu-
gation, plasma was aliquoted and stored below −70 ◦C until further 
analysis. Plasma concentrations of LAAMA were analyzed using a liquid 
chromatography/tandem mass spectrometry (LC/MS/MS) method with 
a calibration range of 1–1000 nM on a QTRAP 6500+ (Sciex, Fra-
mingham, MA, USA). Samples were pretreated with ethanol for protein 
precipitation before the analysis. All procedures were approved by the 
German Veterinary Office under the license n◦ 14-009-G. 
2.2. Functional cAMP assay with stable cell lines 
The in vitro functional cAMP assay was used to measure accumula-
tion of cAMP after receptor activation in cells stably expressing human 
CTR (1321N1 CALCR Gs Cell Line cAMP Hunter™, DiscoverX), human 
CGRPR (1321N1 CALCRL RAMP1 Gs Cell Line cAMP Hunter™, Dis-
coverX) or human ADMR (1321N1 CALCRL RAMP3 Gs Cell Line cAMP 
Hunter™, DiscoverX). Intracellular cAMP increase was measured using 
the AlphaScreen™ cAMP Functional Assay Kit (Perkin Elmer) according 
to the manufacturer’s protocol. Briefly, 5000 cells in 50 μl culture me-
dium were seeded per well in 384-well plates and incubated over night 
at 37 ◦C and 5% CO2. On the day of assay, test compounds were 
reconstituted in DMSO to a 1 mM stock solution and then diluted in 
assay buffer containing 1% DMSO. The assay was started by substitution 
of the culture medium with 10 μl assay buffer containing test com-
pounds. Cells were stimulated with the compounds for 45 min at RT. The 
stimulation was stopped by adding 5.5 μl lysis buffer containing 
streptavidin-coated donor beads/biotinylated cAMP tracer mix and 4.5 
μl lysis buffer containing anti-cAMP conjugated acceptor beads and 
incubated for 2 h at RT in a dark place. The emission was measured at 
520–620 nm on the EnVision™ reader (PerkinElmer). Concentration- 
response data from test compounds were analyzed with XLfit (IDBS) 
software using nonlinear regression applied to a sigmoidal dose- 
response model. cAMP concentration was derived from the cAMP 
standard curve, which was measured parallel to each assay. 
2.3. Functional cAMP assay with transiently transfected COS7 cells 
To assess the potency of LAAMA on calcitonin and amylin receptors 
of different species, cells were transiently transfected with the respective 
expression plasmids. The in vitro functional cAMP assay was used to 
measure accumulation of cAMP after receptor activation in the cells 
transiently transfected with pcDNA3.1 plasmids designed for expression 
of human, rat or mouse CTR alone or together with one of RAMPs. For 
transient transfection, COS7 cells were seeded on 384-well plates (7500 
cells per well in volume of 50 μl culture medium). 25 μl of plasmid DNA/ 
Attractene reagent (Qiagen) mix was added per well and the cells 
incubated for 4 h at 37 ◦C and 5% CO2. The transfection medium was 
then replaced by culture medium (50 μl per well) and the cells incubated 
over night at 37 ◦C and 5% CO2. Intracellular cAMP increase was 
measured using the AlphaScreen™ cAMP Functional Assay Kit (Perkin 
Elmer) as described above. 
2.4. Animal husbandry and diet 
Male RAMP 1/3 KO and WT mice were bred using the following 
breeding scheme: RAMP1/3 KO x RAMP1/3 KO and RAMP3 WT x 
RAMP3 WT (Coester et al., 2020), both genotypes were from the same 
generation F5N1 and were rederived at Janvier Elevage (Le Genest Saint 
Isle, France). Founder animals had been kindly provided by Prof. K. 
Caron, University of North Carolina, USA. Neuron specific CTR KO 
(Nestin-CreCTR) mice were bred at Janvier Elevage (Le Genest Saint Isle, 
France). To generate transgenic WT (Nestin-CreWT) and KO (Nestin--
CreCTR) mice, male CTR floxed mice (Coester et al., 2020) (frozen sperm 
kindly provided by Drs. Jean-Pierre David and Thorsten Shinke, Uni-
versity Medical Center Hamburg) were crossed to female Nestin-Cre 
mice (JAX n◦003771) generating CTRfl/+: Nestin-Cre mice. These mice 
were again crossed with male CTRfl/+ mice to generate the KO (Nes-
tin-CreCTR) mice and the corresponding transgenic control mice (Nes-
tin-CreWT). WT Nestin-WTWT and floxed control mice Nestin-WTCTR 
were also generated. 
Mice were then transferred to the animal facility of the University of 
Zurich at the age of 6–12 weeks. All animals were group-housed at a 
constant temperature of approx. 22 ◦C, relative humidity of approx. 
60%, and kept at a 12 h dark/light cycle with lights off at 10 h. Mice had 
free access to normal chow (65% carbohydrate, 22% protein, and 12.5% 
fat as percent of total energy content, cat. no. 3436; Provimi Kliba, 
Kaiseraugst, Switzerland) and tap water, and the cages were equipped 
with plastic housing and nesting material. After an acclimatization 
period, 7-week-old WT and RAMP1/3 KO and 7-13-week-old Nestin- 
CreWT, Nestin-CreCTR, Nestin-WTWT and Nestin-WTCTR mice were single 
housed to precisely monitor their food intake and were handled daily 
prior to the experiment to reduce stress related to substance adminis-
tration. Two weeks before treatment, mice were placed on 45% high fat 
diet (HFD, 35% carbohydrate, 20% protein, and 45% fat as percent of 
total energy content, cat. no. D12451; Ssniff, Germany). One week 
before the treatment period, mice received daily sham subcutaneous 
injection of saline (NaCl 0.9%). 
All animal experimental protocols in this study were approved by the 
University of Zurich Animal Protection Office and Ethics committee, the 
Veterinary Office of Canton Zurich (License n◦ 102/2018), and conform 
to Swiss Animal Protection guidelines and regulations (Swiss Animal 
Protection and Swiss Animal Act and Ordinance) and in accordance with 
the EU Directive on the protection of animals used for scientific pur-
poses. These studies adhere to the ARRIVE guidelines. 
2.5. Effect of LAAMA on body weight and food intake 
After 2 weeks of HFD, single housed mice were injected subcutane-
ously daily for 7 days 1 h before dark onset. The RAMP 1/3 KO exper-
iment consisted of four groups (n = 12–15/group): WT-Vehicle (D- 
Mannitol 200 mM) and WT-LAAMA (10 nmol/kg), and RAMP 1/3 KO- 
Vehicle and RAMP 1/3 KO-LAAMA (10 nmol/kg), respectively. The 
experiment with CTR KO mice also consisted of four groups (n = 19–20/ 
group): Nestin-CreWT and Nestin-CreCTR were both injected with vehicle 
or LAAMA (10 nmol/kg). Food intake and body weight were measured 
daily and manually recorded. 
To avoid possible degradation during long-term storage, LAAMA was 
freshly dissolved on each day of the study. 
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2.6. Mice killing and perfusion 
Mice used to assess the effect of LAAMA on body weight and food 
intake were anesthetized with pentobarbital (100 mg/kg, i.p.; Kant-
onsapotheke Zurich, Switzerland) after 24 h from the last LAAMA in-
jection. Blood was collected by terminal cardiac puncture into KEDTA 
tubes. Carcasses were stored at −20 ◦C until Echo-MRI scan analysis. 
After a 12 h fast, to assess CTR immunostaining and LAAMA-induced 
c-Fos, separate cohorts from RAMP1/3 KO and Nestin-CreCTR mice col-
onies were injected i.p. with LAAMA (10 nmol/kg) or vehicle. 90 mins 
later, mice were anesthetized with pentobarbital (100 mg/kg, i.p.) and 
perfused for 1.5 min with 0.1 M phosphate buffer followed by 4% 
paraformaldehyde in 0.1 M phosphate buffer (PB-PFA, pH 7.4) for 2.5 
min. Brains were isolated and postfixed overnight in 4% PB-PFA fol-
lowed by overnight cryoprotection in 20% sucrose-0.1 M PB. They were 
then frozen in hexane on dry ice for 3 min and stored at −80 ◦C. Frozen 
hindbrains were cut at 20 μm in 3 series across the AP/NTS region and 
were mounted onto superfrost plus slides (Life Technologies Europe, 
Zug, Switzerland). Slides were stored in cryoprotectant (50% 0.02 M 
KPBS, 30% ethylene glycol, 20% glycerol) at −20 ◦C until staining for 
amylin-induced c-Fos and CTR fibers immunohistofluorescence (IHF) in 
the AP (Coester et al., 2020). 
2.7. Echo-MRI analysis 
Body composition of mice of all groups was measured post-mortem 
using an EchoMRI™ body composition analyzer (Zurich Integrative 
Rodent Physiology, UZH). Animals were placed in a plastic holder which 
was inserted in a tubular space in the EchoMRI™ system and body fat 
and lean mass were measured as a percent of body weight. Each mea-
surement was performed in duplicate. 
2.8. Immunohistofluorescence 
2.8.1. c-Fos staining 
Brain AP sections were washed in 0.02 M KPBS before being blocked 
for 2 h with 3% normal donkey serum (NDS), 0.3% Triton X-100 in 0.02 
M KPBS at room temperature (RT). Single-label c-Fos IHF was carried 
out using rabbit anti-c-Fos antibody (1:500; 2250, Cell Signaling Tech-
nologies, BioConcept, Allschwil, Switzerland) and slides were incubated 
for 48 h at 4 ◦C. Slides were washed in 0.02 M KPBS 5 times for 5 min 
and incubated for 2 h with Cy3 donkey anti-rabbit antibody (1:100, 711- 
165-152, Jackson ImmunoResearch, LubioScience, Luzern, 
Switzerland). Sections were then counterstained with DAPI, and cov-
erslipped using Vectashield Hardset mounting medium (Vectorlabs, 
Servion, Switzerland). 
2.8.2. Calcitonin receptor staining 
Brain AP sections were washed in 0.1% PBST (0.1% Triton X-100 in 
0.01 M PBS) before being blocked for 90 min at RT with 3% NDS, 0.3% 
Triton X-100 in 0.01 M PBS. Slides were washed in 0.1% PBST and 
incubated for 48 h at 4 ◦C with rabbit anti-CTR antibody (1:1000, 
ab11042, Abcam, Cambridge, UK) in 0.3% PBST. Slides were washed 
twice in 0.01 M PBS followed by 10 min in 0.1% PBST. Secondary 
antibody (Alexa 647 donkey anti-rabbit 1:100 in 0.3% PBST, 711-605- 
152, Jackson ImmunoResearch) was then applied for 2 h at RT (Duffy 
et al., 2018; Potes et al., 2012). Finally, sections were washed in 0.01 M 
PBS, counterstained with DAPI, and coverslipped using Vectashield 
Hardset mounting medium. 
2.9. Quantitative analysis of immunolabelled cells and fibers 
C-Fos expressing neurons in the AP were imaged using an L2 Imager 
upright microscope (Zeiss, Germany). Images were set to the same 
threshold and c-Fos-positive neurons were quantified using ImageJ 
(NIH). Three AP sections were used for quantification. 
For the quantitative analysis of CTR fiber density, three sections 
through the AP were acquired using a Zeiss SP8 confocal system 
equipped with a 20 × 0.75 objective (HD1 405, laser 29% with 471.3% 
gain, HyD3 laser 5% with 317% gain, laser zoom 1, pinhole 1, Z stack 19 
μm, step of 1.5 μm). Slides were numerically coded to blind the exper-
imenter. Image analysis was performed using ImageJ analysis software 
(NIH) as previously described (Lutz et al., 2018). Briefly, each image 
plane was set to a threshold and binarized. The integrated intensity, 
which reflects the total number of pixels in the binarized image, was 
then calculated. This procedure was conducted for each image plane in 
the stack, and the values were summed. The resulting value is an ac-
curate index of the density of the nerve processes in the volume sampled. 
The same microscope setup (including objective, zoom, laser power, 
gain) was used to acquire all images within the same experiment. For 
representative images, images were equally adjusted for brightness and 
contrast within the same experiment. 
2.10. Statistics 
Statistical analysis was performed using unpaired t-test, 2-way 
ANOVA with repeated measure and 3-way ANOVA (factors: time, ge-
notype and treatment), as appropriate, with multiple comparison post- 
hoc analysis using GraphPad prism 8 software. 
3. Results 
3.1. LAAMA is equipotent on human CTR and AMYs and its potency is 
conserved between human and rodent receptors 
The pharmacological activity of LAAMA was evaluated in 1321N1 
cells stably expressing human CTR, CGRPR (CLR + RAMP1) and ADMR 
(CLR + RAMP3) using a Gs mode cAMP assay (as a surrogate for 
pathway activation). Full concentration-responses (0.1 pM–10 μM) of 
LAAMA, human amylin, calcitonin (CT), CGRP and rat ADM were tested 
to compare the potency and selectivity of LAAMA to endogenous li-
gands. As shown in Fig. 1A and Table 1, LAAMA potently activated hCTR 
in a concentration-dependent manner. With the EC50 value of 1.5 nM, it 
was slightly less potent at the hCTR than hCT but approx. 4-fold more 
potent than hAmylin (Fig. 1A, Table 1 and Suppl. Table 1). LAAMA did 
not activate hCGRPR and hADMR in the cAMP assay at any concentra-
tion tested (Fig. 1B and C and Table 1), suggesting high selectivity for 
CTR. In vitro functional cAMP assay with transiently transfected COS7 
cells showed that LAAMA was equipotent on all three AMYs (Fig. 1D–G) 
and LAAMA compound action on CTR was preserved between human, 
rat and mouse (Fig. 1G–I). 
3.2. LAAMA is a long acting peptide 
LAAMA is a peptide stabilized by lipidation, which facilitates binding 
to serum albumin to prevent a fast excretion by kidney. The PK of the 
LAAMA in plasma was investigated in lean rats following i.v. and s.c. 
administration. The terminal half-life in lean rats was 34 h, as desired for 
a long-acting peptide. A maximum concentration of 78.7 nM after a 
single s.c. administration of 20 nmol/kg was reached at 24 h post dose. 
PK in mouse has been assessed for similar peptides from the same pep-
tide class with the identical half-life extension as the here described 
LAAMA and were comparable to rat PK results. 
3.3. Effect of repeated administration of LAAMA on food intake and body 
weight in WT and RAMP1/3 KO mice 
To test whether body weight and food intake lowering effects of 
LAAMA require RAMP1/3, WT and RAMP1/3 KO mice kept on HFD 
were once-daily s.c. injected with vehicle or 10 nmol/kg LAAMA over 
the period of 7 days. Body weight (Suppl. Fig 1A) was calculated as 
cumulative body weight gain (Fig. 2A) or as a percent of baseline (Suppl. 
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Fig 1B). Repeated treatment with LAAMA significantly decreased body 
weight in WT and RAMP 1/3 KO mice compared to their respective 
controls. (Fig. 2A and Suppl. Fig. 1A and B). Daily food intake was 
similar among the four groups, though a slight tendency towards 
reduced food intake was observed in the LAAMA treated when 
compared to vehicle treated groups, however without being statistically 
significant (Fig. 2B and Suppl. Fig.1C). There was no effect of LAAMA on 
terminal glucose levels in WT or KO mice (Fig. 2C). However, glucose 
was higher in WT-Vehicle group compared to RAMP 1/3 KO-Vehicle (P 
= 0.0017) and to RAMP 1/3 KO-LAAMA mice (P = 0.0004; Fig. 2C). WT- 
LAAMA mice also showed higher glucose levels compared to RAMP1/3 
KO-LAAMA mice (P = 0.0041; Fig. 2C). Body composition analysis did 
not reveal any statistically significant difference among the groups 
(Fig. 2D and E). 
3.4. LAAMA induces a c-Fos response in the area postrema of WT mice 
only 
To test whether LAAMA activates neurons in the AP (the brain region 
known to express CTR and RAMPs and to mediate the eating-inhibitory 
effect of endogenous amylin (Lutz et al., 2001; Mollet et al., 2004)) and 
whether this effect requires intact RAMP1/3, the c-Fos response was 
measured in WT and RAMP1/3 KO mice peripherally treated with 
vehicle or 10 nmol/kg LAAMA. The overall cell count was low, but 
LAAMA induced a 9-fold increase in the c-Fos response in the AP of WT 
mice compared to vehicle controls (P = 0.029; Fig. 3A and B). C-Fos 
response was also increased in the AP of RAMP1/3 KO mice (Fig. 3A and 
B) compared to their vehicle injected counterpart, however, this effect 
was statistically not significant. 
3.5. Effect of repeated administration of LAAMA on food intake and body 
weight in Nestin-CreWT and Nestin-CreCTR mice 
To test whether the effects of LAAMA on food intake and body weight 
are mediated by neuronal CTR, we next depleted CTR from Nestin 
positive neurons. 
Among the 4 mouse groups, Nestin-WTWT and Nestin-WTCTR dis-
played higher body weight than Nestin-CreCTR and Nestin-CreWT sug-
gesting that the cre phenotype is significantly different than the WT 
phenotype (Suppl. Fig. 2A–C). Thus, the Nestin-CreWT mice were chosen 
as controls for the following experiments. 
The neuronal CTR-KO (Nestin-CreCTR) mice and corresponding 
control (Nestin-CreWT) mice were kept on HFD and peripherally treated 
with 10 nmol/kg LAAMA (once-daily, over a period of 7 days). Treat-
ment with LAAMA significantly reduced body weight gain of Nestin- 
CreWT mice compared to their respective vehicle-treated group (Fig. 4A, 
Supp. Fig. 3A and B). Body weight gain of Nestin-CreCTR mice was also 
Fig. 1. LAAMA is equipotent on human CTR/CALCR and AMYs and its action is conserved between human and rodent receptors. (A–C) Representative 
concentration-response curves showing cAMP accumulation in cells stably expressing (A) hCTR, (B) hCLR + Ramp1 (C) hCLR + Ramp3 after activation with LAAMA, 
hAmylin, hCalcitonin, hCGRP and rAdrenomedullin. (D–I) Representative concentration-response curves showing cAMP accumulation in cells transfected with (D) 
hAMY1, (E) hAMY2, (F) hAMY3, (G) hCTR, (H) rat CTR, (I) mouse CTR after activation with LAAMA. Abbr. hCTR -human calcitonin receptor, RAMP-receptor 
activity modifying protein, cAMP- cyclic adenosine monophosphate, hCGRP- human calcitonin gene-related peptide, hAMY-human amylin receptor, EC50-half 
maximal effective concentration, value is the geometric mean of three independent experiments. 
Table 1 
Activity of LAAMA, human amylin, human calcitonin (hCT), hCGRP and rat 
adrenomedullin (rAMD) on human calcitonin receptor (hCTR), hCGRPR, 
hAMDR. (relates to Fig. 1). EC50 is calculated as the geometric mean of three 
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reduced when treated with LAAMA compared to their respective vehicle 
group, however this effect was significantly weaker than for Nestin- 
CreWT mice (Fig. 4A, Supp. Fig. 3A and B). In line with the effects on 
body weight, cumulative food intake was reduced in LAAMA-treated 
Nestin-CreWT animals compared to the respective non-treated group. 
On the contrary, LAAMA did not reduce daily food intake in Nestin- 
CreCTR mice (Fig. 4B, Suppl. Fig.3C). 
3.6. LAAMA does not induce a c-Fos response in Nestin-CreCTR mice 
compared to Nestin-WTCTR 
To confirm the mouse model, CTR fiber immunodensity was quan-
tified in the AP of vehicle injected mice, with Nestin-CreCTR mice 
showing an 86% decrease compared to Nestin-CreWT group (P < 0.05; 
Fig. 4C and D). 
To test whether the activation of AP neurons by LAAMA requires 
intact CTR, Nestin-CreCTR and Nestin-WTCTR mice were peripherally 
injected with LAAMA (10 nmol/kg). Treatment with LAAMA induced an 
18-fold increase of c-Fos in Nestin-WTCTR compared to their vehicle- 
treated counterpart (p = 0.0144; Suppl. Fig. 4A and B). In contrast, no 
c-Fos induction was observed in Nestin-CreCTR mice (Suppl. Fig. 4A and 
B). 
4. Discussion 
In order to investigate the role of the different AMY components in 
conveying the effects of LAAMA on eating and body weight, we deter-
mined LAAMA’s in vitro potency on CTR, AMYs, CGRPR and ADMR and 
in vivo efficacy in RAMP 1/3 KO and Nestin-CreCTR mice. First, we 
showed that LAAMA equipotently activated CTR and AMYs in vitro, 
while being inactive on other tested receptors. Moreover, potency of 
LAAMA is preserved between human, rat and mouse CTRs, making it a 
Fig. 2. Effect of LAAMA on food intake 
and body weight in WT and RAMP1/3 KO 
mice compared to vehicle. 
(A) Cumulative body weight gain over the 7 
day-period; (B) Cumulative food intake over 
the 7 day-period; (C) Glucose at sacrifice in 
mmol/L; (D) Fat mass at sacrifice expressed 
as a percent of final body weight; (E) Lean 
mass at sacrifice expressed as a percent of 
final body weight. Data are presented as 
mean ± S.E.M., N = 12–15/group. Statistics: 
Data are analyzed with a 3-way and 2-way 
ANOVA (factors: genotype, treatment (RX) 
and time) followed by Tukey’s multiple 
comparisons test. Parameters with differing 
letters (a, b, c, d) differ from each other by at 
least P < 0.05. *P < 0.05; **P < 0.01, ***P 
< 0.001, ns: not significant.   
Fig. 3. LAAMA induces a c-Fos response in the 
area postrema (AP) of WT mice only. 
(A) Quantification of c-Fos positive neurons; (B) 
Representative images of AP brain sections immu-
nostained for c-Fos in WT vs. RAMP1/3 KO male 
mice 90 min after vehicle or LAAMA (10 nmol/kg) 
injection (20× magnification). Values are presented 
as mean ± S.E.M. n = 4–7/group. Statistics: two- 
way ANOVA (mixed effect analysis) followed by 
Tukey’s multiple comparisons test and unpaired T- 
test. *P < 0.05. ns: not significant.   
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suitable tool for in vivo studies in both rodent species. In vivo, LAAMA 
decreased body weight gain in WT as well as in RAMP 1/3 KO mice, 
indicating that RAMP1/3 are not crucial for LAAMA-induced effects. In 
contrast, absence of neuronal CTR (Nestin-CreCTR) resulted in less pro-
nounced reduction of body weight after treatment with LAAMA, sug-
gesting that neuronal CTR is the main mediator of LAAMA’s body weight 
lowering effects. 
In vitro studies showed that LAAMA equipotently increased intra-
cellular cAMP, an established marker of AMYs and CTR activation (Ar-
mour et al., 1999; Gingell et al., 2014; Perry et al., 1997; Qi et al., 2013; 
Udawela et al., 2006), after binding to CTR or AMYs. This suggests that 
unlike amylin, LAAMA’s efficacy to activate downstream signaling 
pathways in CTR expressing cells is not altered by RAMPs. It is important 
to consider that even though the increase of intracellular cAMP after 
LAAMA or amylin treatment means that the receptor has been activated 
in vitro (Bower and Hay, 2016), it is not always accompanied by an 
anorectic effect in vivo (Hay et al., 2015). C-Fos, on the other hand, has 
been traditionally shown as a marker of neuronal activation in vivo after 
amylin treatment (Barth et al., 2004; Christopoulos et al., 1995; Riediger 
et al., 2004; Sexton et al., 1994). Our in vivo studies showed that LAAMA 
increased c-Fos by 9-folds and 18-folds in the AP of WT and transgenic 
Nestin-Cre control mice, respectively, compared to vehicle-treated ani-
mals. RAMP 1/3 KO mice had a partial, although not statistically sig-
nificant c-Fos response to LAAMA, but notably, the overall number of 
c-Fos positive neurons was low. We have previously shown that RAMP 
1/3 KO mice display a strong decrease in CTR density in the AP (Coester 
et al., 2020), which may have contributed to the lower number of 
LAAMA induced c-Fos positive cells as we have also seen with amylin 
(Coester et al., 2020). This assumption agrees with the results obtained 
from the Nestin-CreCTR mice. In these animals, injection of LAAMA had 
no measurable c-Fos response. Our results of c-Fos induction in vivo 
confirmed in vitro data indicating that CTR expressing cells with or 
without RAMPs can mediate LAAMA’s effects. In line with this conclu-
sion, LAAMA reduced body weight gain to the same extent in both, WT 
and RAMP1/3 KO mice. Unchanged food intake suggests that LAAMA 
may induce body weight loss through increased energy expenditure, but 
further studies are needed to confirm this hypothesis. 
The importance of neuronal CTR for the effects of LAAMA on body 
weight was confirmed by the results obtained from the Nestin-CreCTR 
mice. These animals were less responsive to the repeated LAAMA 
administration than the transgenic controls (Nestin-CreWT). CTR fiber 
density staining in the AP of Nestin-CreCTR and the transgenic control 
mice confirmed the absence of neuronal CTR. 
5. Conclusion 
Our research advanced the understanding of LAAMA’s actions in vivo 
and in vitro. We demonstrated that the novel drug LAAMA binds CTR and 
AMYs equipotently in vitro and induces intracellular cAMP synthesis. In 
vivo, LAAMA significantly reduced body weight in WT and in RAMP 1/3 
KO mice, while animals with the neuronal CTR KO were less responsive 
showing that unlike amylin, LAAMA does not necessarily require RAMPs 
to reduce body weight and that LAAMA effects are mainly mediated by 
the neuronal CTR. 
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